Findings

What do systematic reviews say?

5 questions · 5 findings · 3 reviews

No studies found 2 · 40%GRADE not reported 0 · 0%Very low 2 · 40%Low 0 · 0%Moderate 0 · 0%High 1 · 20%

Quality of life · relapsing multiple sclerosis

The review found no eligible studies for this question.

1 finding from 1 review

Rituximab for people with multiple sclerosis 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Quality of life · primary progressive multiple sclerosis

The review found no eligible studies for this question.

1 finding from 1 review

Rituximab for people with multiple sclerosis 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Quality of life · thyroid‐associated ophthalmopathy

1 finding from 1 review

Rituximab for thyroid‐associated ophthalmopathy 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 25 participants
Very low

Health‐related quality of life · patients with rheumatoid arthritis

Rituximab (2 x 1000 mg) plus methotrexate leads to higher health‐related quality of life compared with methotrexate monotherapy (high certainty).

1 finding from 1 review

Rituximab for rheumatoid arthritis 2015 · Cochrane Headline outcomes only
RR 2 [1.1, 3.4]
4 studies · 1526 participants
High

Quality of life improvement by at least 6 points · thyroid‐associated ophthalmopathy

1 finding from 1 review

Rituximab for thyroid‐associated ophthalmopathy 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 27 participants
Very low